Interferon-beta (Human, Recombinant)

• Short Description:

  Catalog Number: B2010306 (10 ug)_x000D_ Interferon-beta (Human, Recombinant) is a high quality research product used as highly pure Interferon-beta (Human, Recombinant) expressed in HEK293. This protein acts as a cytokine with known immunomodulatory properties. This protein has been used to study COVID-19 whereby it was found to decrease viral load and improve lung condition in a marmoset model. Custom bulk orders of this product are available upon request.

• Description:

  Interferon-beta (Human, Recombinant)_x000D_ Catalog number: B2010306_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Volume/Weight: 10 ug_x000D_ pH: 7.4 upon reconstitution_x000D_ Supplied as: Lyophilized Powder_x000D_ Appearance: Powder_x000D_ Applications: highly pure Interferon-beta (Human, Recombinant) expressed in HEK293. This protein acts as a cytokine with known immunomodulatory properties. This protein has been used to study COVID-19 whereby it was found to decrease viral load and improve lung condition in a marmoset model._x000D_ Storage: -20C_x000D_ Keywords: rHuIFN-β; IFNB_x000D_ Grade: Biotechnology grade. All components are highly pure (minimum 95%). All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ References:_x000D_ 1: Haji Abdolvahab M, Mofrad MR, Schellekens H. Interferon Beta: From Molecular_x000D_ Level to Therapeutic Effects. Int Rev Cell Mol Biol. 2016;326:343-72._x000D_ _x000D_ 2: Markowitz CE. Interferon-beta: mechanism of action and dosing issues._x000D_ Neurology. 2007 Jun 12;68(24 Suppl 4):S8-11._x000D_ _x000D_ 3: Wanve M, Kaur H, Sarmah D, Saraf J, Pravalika K, Vats K, Kalia K, Borah A,_x000D_ Yavagal DR, Dave KR, Bhattacharya P. Therapeutic spectrum of interferon-β in_x000D_ ischemic stroke. J Neurosci Res. 2019 Feb;97(2):116-127._x000D_ _x000D_ 4: Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM,_x000D_ Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette_x000D_ DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP,_x000D_ Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH,_x000D_ et al. Intramuscular interferon beta-1a for disease progression in relapsing_x000D_ multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)._x000D_ Ann Neurol. 1996 Mar;39(3):285-94._x000D_ _x000D_ 5: Zhou X, Tang G. Intravenous Interferon β-1a for Severe ARDS. JAMA. 2020 Aug_x000D_ 4;324(5):515._x000D_ _x000D_ 6: Placebo-controlled multicentre randomised trial of interferon beta-1b in_x000D_ treatment of secondary progressive multiple sclerosis. European Study Group on_x000D_ interferon beta-1b in secondary progressive MS. Lancet. 1998 Nov_x000D_ 7;352(9139):1491-7._x000D_ _x000D_ 7: Randomised double-blind placebo-controlled study of interferon beta-1a in_x000D_ relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and_x000D_ Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study_x000D_ Group. Lancet. 1998 Nov 7;352(9139):1498-504._x000D_ 8: McCormack PL, Scott LJ. Interferon-beta-1b: a review of its use in relapsing-_x000D_ remitting and secondary progressive multiple sclerosis. CNS Drugs._x000D_ 2004;18(8):521-46. _x000D_ _x000D_ Products Related to Interferon-beta (Human, Recombinant) : Proteins

• CAS Number:

  9000-83-3

• Weight:

  0.15

• Length:

  2

• Width:

  0.5

• Height :

  0.5